Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
about
Animal Models for HIV Cure ResearchConsiderations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategiesRectal pre-exposure prophylaxis (PrEP)New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyondPersistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV modelExposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaquesAnimal models for HIV/AIDS researchMacaques as model hosts for studies of HIV-1 infectionRT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.Prophylactic and therapeutic effect of AZT/3TC in RT-SHIV infected Chinese-origin rhesus macaquesImmunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirsViral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS.Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDSA spatio-temporal assessment of simian/human immunodeficiency virus (SHIV) evolution reveals a highly dynamic process within the host.Dysregulation of multiple inflammatory molecules in lymph node and ileum of macaques during RT-SHIV infection with or without antiretroviral therapyNonhuman primate models for HIV cure research.Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy.A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy.Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAARTWell-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy.Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.Ultrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer designBreaking Barriers to an AIDS Model with Macaque-Tropic HIV-1 Derivatives.A macaque model of HIV-1 infectionRobust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infectionSuppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gaRT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models.Variation of human immunodeficiency virus type-1 reverse transcriptase within the simian immunodeficiency virus genome of RT-SHIV.Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon.A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potentialRevising the Role of Myeloid cells in HIV Pathogenesis.Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy.
P2860
Q26767476-CB36ED3C-7FEF-42F7-BBEF-1F9315A0782BQ26825814-CD965675-8954-4F74-A41A-9C4C5E60A329Q26829713-D811B7FD-5D39-4BF6-9433-2706377C4D34Q27027164-7DB87FCB-DD7A-4D1C-8343-D78B82248744Q27335485-B6516A21-6469-4010-A3F5-6F821ABCE39EQ28540200-65136123-7DFA-4986-AFCD-2907F75E23E7Q30423656-72BBE327-D00C-498D-8851-DE4D104EFE62Q30653348-E08C029B-4A97-4FF4-8895-751934AC7804Q33514943-929E355D-ECA4-468B-9349-E88579436D37Q33592750-3F43A3F3-1E3B-4C40-8300-1779865480CEQ33604776-05D07E44-D53B-4535-8A44-03C8C7F707F1Q33644248-60796185-2B09-4CD2-913D-3BA3F6DEE229Q33676630-4BB80297-6898-4050-ABFD-C3462B4DB2CCQ33728690-43C1B4F4-1D0F-4BEE-B86D-294AE68FA1B8Q34250336-26B91386-84D4-4A0E-BBB8-06CD86A059C7Q34407781-55BD22F9-957B-469F-A92F-7E6FA595F0F7Q34485122-83D52F5C-501F-44A5-B10C-D936FE294C0AQ34990151-BB2358CC-E880-4F62-BEF9-B4CD63D2A02EQ35088292-EA4DAC6A-8483-4C7A-A862-4E75E4CA31BFQ36273849-1FEB311B-2260-4B3D-A4E7-14B75EF78395Q36290753-B8D61D97-91E6-4FB3-8AB0-7416B7418428Q36397557-D138202F-9EAA-42E8-BFEE-2D6C6B019A7FQ36525986-90E929F7-296F-462B-BC9F-263D78235044Q36537806-647A9E44-2136-44C7-9BA4-5E317217BCC8Q37132808-B4322FC1-AB3C-4128-9D04-0F22CD34A69DQ37169285-FCBD2D0F-BC6B-4CC3-A22F-487799E5B470Q37275103-89FB7837-307E-48E4-B887-2F7CF6CCA273Q37428359-BC18C295-064F-440B-A40B-9384EC94A2CDQ37538534-1611CA11-1A8B-4ECC-9DFE-737DC0662D64Q37582339-1F4E0D49-3389-48DC-BA08-9E184EC9B3E9Q40088680-F8AC6C2C-F489-4700-B3A5-CD1590D43E63Q42701528-EC6303D8-BBC7-487E-83E3-AED95A12D485Q45252370-E9F937C6-4516-4287-8022-53719ECB670FQ45326424-BB85521E-CDD5-466E-B382-838CA5BCF409
P2860
Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Suppression of viremia and evo ...... el for antiretroviral therapy.
@ast
Suppression of viremia and evo ...... el for antiretroviral therapy.
@en
type
label
Suppression of viremia and evo ...... el for antiretroviral therapy.
@ast
Suppression of viremia and evo ...... el for antiretroviral therapy.
@en
prefLabel
Suppression of viremia and evo ...... el for antiretroviral therapy.
@ast
Suppression of viremia and evo ...... el for antiretroviral therapy.
@en
P2093
P2860
P50
P356
P1433
P1476
Suppression of viremia and evo ...... el for antiretroviral therapy.
@en
P2093
Frank Maldarelli
Jeffrey D Lifson
John M Coffin
John W Mellors
Kay Larsen
Kelli Oswald
Leon Flanary
Michael Piatak
Norbert Bischofberger
Patricia Polacino
P2860
P304
12145-12155
P356
10.1128/JVI.01301-07
P407
P577
2007-09-12T00:00:00Z